ASH 2016 Abstract 1151. Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux
Saad Z. Usmani et al.
Results: Progression-free survival in patients with 1 to 3 prior lines of therapy and treatment-free interval of (A) >12 months (B) ≤12 months prior to randomization
Conclusions: Responses with DRd were deep and durable which translated into significantly improved clinical outcomes vs Rd in 1-3 PL pts with RRMM. The results of these subgroup analyses suggest that the treatment benefit of DRd vs Rd was maintained across these subgroups, including pts with TFI of ≤12 months and those who were refractory to their last line of therapy.
ASH 2106 Abstract 1150. Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor
Maria-Victoria Mateos et al.
Results: Progression-free Survival in High-risk Patients (Defined by Cytogenetic Abnormalities) who Received 1 to 3 Prior Lines of Therapy
Conclusions: The treatment benefit of DVd vs Vd was maintained across 1-3 PL and 1 PL pts. Responses for DVd were deep and durable and correlated with significantly improved outcomes vs Vd. Despite small group sizes, treatment benefit of DVd vs Vd was also observed in high-risk cytogenetic pts receiving 1-3 PL. These data continue to support daratumumab- containing regimens in RRMM.
CARE Faculty Perspective: Daratumumab recently received breakthrough designation from the FDA for use in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone in the second-line MM setting based on the phase III CASTOR and POLLUX trials published earlier this year. Updated analysis from these trials were presented during ASH 2016 and confirmed the safety and efficacy of these daratumumab containing regimens. The results of these trials are particularly interesting considering that the demonstrated benefit was maintained across patients regardless of time since last treatment, cytogenetic risk, or refractoriness to previous lines of therapy.
Related abstract of interest with additional CASTOR and POLLUX analysis: 246. Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone